GLP-1 Medicines Before Surgery in South Africa: A Plan, Not a Blanket Stop Rule

Why this matters for a South African appointment

A 2025 editorial in the Southern African Journal of Anaesthesia and Analgesia connects two problems: unnecessarily long preoperative fasting in local hospitals, and the added complexity of GLP-1 medicines. It calls for clearer responsibilities and individualised assessment, with gastric ultrasound where available. It is published professional commentary, not a national GLP-1 protocol or a trial proving a particular stopping interval.²

This guide was prepared on 21 September 2026 as original editorial synthesis of existing sources. It is not a new September safety alert, original patient reporting or a clinician-reviewed treatment plan. Our South African focus is the practical handover between your prescriber, the hospital or day clinic and the anaesthesia team—not an assumption that overseas guidance automatically governs every local facility.

The warning: fasting and an empty stomach are not identical

The UK MHRA’s 28 January 2025 safety communication explains that GLP-1 and dual GIP/GLP-1 medicines can slow stomach emptying. Contents may remain despite routine fasting and could enter the lungs during general anaesthesia or deep sedation. This is the aspiration concern. The MHRA calls for individual assessment and notes that evidence was insufficient to recommend one universal pause interval.¹

This is relevant to procedures involving deep sedation as well as operations. Do not assume a short procedure makes disclosure unnecessary. Equally, a warning about a possible complication is not a prediction that it will happen to you. Those are different statements, and responsible advice keeps them separate.

What the human evidence can—and cannot—tell us

A US retrospective study published in JAMA Network Open on 4 March 2025 examined 366,476 adults undergoing 14 common operations; 5,931 had a preoperative GLP-1 prescription. It found no statistically significant association with postoperative aspiration pneumonia after adjustment: odds ratio 0.78, with a 95% confidence interval of 0.57–1.06.³

That is reassuring observational evidence, not proof of zero risk. Prescriptions were a proxy for actual use, so the researchers could not establish every patient’s medicine-taking behaviour. The study was not a randomised comparison of continuing versus stopping treatment, nor a South African risk estimate.³ Our interpretation: do not convert either case reports or a reassuring cohort result into a universal personal instruction.

Why guidance does not reduce to a seven-day rule

The US multi-society guidance announced on 29 October 2024 says most patients can continue GLP-1 medicines before elective surgery. It identifies higher-risk circumstances, including recently starting treatment or increasing a prescribed dose, significant gastrointestinal symptoms and other conditions that slow stomach emptying. For selected patients, the team may use a liquid-only diet for 24 hours, adjust anaesthesia, assess the stomach by ultrasound or defer the procedure.⁴ These are clinician-selected measures, not a do-it-yourself preparation schedule.

A separate UK multidisciplinary consensus statement published in 2025 also supports continuing GLP-1 medicines with risk assessment and measures to reduce aspiration risk. It cautions that upper gastrointestinal symptoms alone should not determine stomach contents and acknowledges limitations in the evidence base.⁵ Neither document removes the need for instructions tailored to the exact procedure and patient.

For a patient in South Africa, the practical conclusion is to obtain a written, agreed plan from the treating team. If an old message says to stop and a newer instruction says to continue, ask the anaesthetist and prescriber to reconcile them. Do not choose between conflicting instructions by counting online recommendations.

A three-part handover to prepare before admission

Keep a copy on your phone or paper and bring the labelled packaging or a photograph if available. Record uncertainties honestly: an unlabelled vial or an unclear ingredient needs to be disclosed, not translated into a familiar brand name. Ask which practice or hospital number to use if you develop new symptoms or the procedure time changes.

If you take treatment for diabetes, ask who will coordinate glucose monitoring and any medication changes around admission. The UK consensus emphasises balancing aspiration precautions against metabolic consequences.⁵ A plan that covers only the last injection but not the rest of your medicines is an incomplete conversation.

Do not try to compensate by fasting for longer

The South African editorial highlights dehydration, hypoglycaemia and discomfort associated with prolonged fasting.² Follow your own team’s food and fluid instructions. Do not add an extra fasting day, start a liquid diet or change medicines because another patient describes doing so. If instructions are unclear, contact the facility rather than improvising.

Medicine status remains a separate question

Approved-medicine information applies to the specific authorised product and indication; your pharmacist or prescriber should verify its South African status. Human perioperative studies do not establish that an online research-labelled vial is an equivalent medicine. Preclinical experiments and veterinary findings cannot supply a human anaesthesia plan. Unsupported claims that a supplement, longer fast or fixed pause guarantees safety should not substitute for assessment.

For suspected medicine side effects in South Africa, SAHPRA’s Med Safety service accepts reports from patients and healthcare professionals; select South Africa in the app.⁶ Reporting does not replace treatment or urgent assessment. The useful outcome of this article is a better-documented clinical conversation, not a purchase or a self-directed protocol.